Iradimed (IRMD) posted earnings growth of 10.8% for the most recent year, which trails its robust 32.3% average annual gain over the past five years. Profit margins dipped slightly to 26.6% from last year’s 26.8%. With both earnings and revenue projected to increase in the near term, investors are weighing the company’s solid growth record against a valuation that sits well above industry and peer averages.

See our full analysis for IRADIMED.

Next, we will see how these headline figures compare to the most widely followed narratives around Iradimed, highlighting where reality and expectations align or diverge.

See what the community is saying about IRADIMED

The newly FDA-approved 3870 MRI-compatible IV pump is expected to drive a major replacement cycle. Analysts believe this will contribute to a revenue growth rate of 10.2% per year over the next three years.

According to the analysts' consensus view, the combination of higher average selling prices for the new pump and ongoing investments in operational capacity could lift profit margins from the current 26.6% to 27.3% by 2026.

The consensus narrative notes that orders for the upgraded 3870 are building a record backlog, supporting stronger cash flows and improved revenue visibility.

While expectations for a broadened addressable market may be justified by rising customer adoption, heavy reliance on a narrow product line leaves the company vulnerable if new competitive technologies emerge.

Analysts expect earnings to grow from $20.7 million today to $28.3 million by 2028, an increase of roughly 37% over the forecast period. ???? Read the full IRADIMED Consensus Narrative.

IRADIMED's core growth remains heavily concentrated in MRI-compatible pumps and monitors. This creates a significant concentration risk if demand shifts, as noted by the consensus narrative.

Bears argue that ongoing supply chain risks and a limited R&D pipeline could restrict future innovation and margin expansion.

Critics highlight that new tariffs or global cost pressures could weigh on gross margins, especially as inventory built up before tariffs is depleted.

The long five to six month backlog for fulfillment of pumps means any regulatory or supply disruption could cause revenue and earnings volatility at a critical transition phase.

IRADIMED currently trades at a Price-to-Earnings ratio of 47.3x, versus the industry average of 27.7x and peer average of 34.2x. This is well above its DCF fair value of $37.82 given the latest share price of $84.11.

The analysts' consensus view is that even if earnings reach $28.3 million and profit margins rise to 27.3% by 2028, the company would still be valued at a 38.5x PE, a premium to the sector.

The consensus narrative adds that the analyst price target of 86.5 is only slightly above the share price, signaling the company may already be fairly valued relative to its growth prospects.

While a track record of strong average growth supports the premium, excess valuation compared to industry benchmarks could put pressure on the stock if future results disappoint.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for IRADIMED on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Want to put your own spin on the numbers? Share your outlook and craft a unique narrative in just a few minutes. Do it your way

A great starting point for your IRADIMED research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Iradimed’s premium valuation could subject shares to pressure if growth slows or if margin expansion fails to meet high investor expectations.

If you’re looking for stocks with more attractive price tags and greater long-term upside, check out these 840 undervalued stocks based on cash flows to discover companies that may be truly undervalued based on future cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include IRMD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com